L'Oréal Group, the global beauty giant, officially announced a minority equity investment in VEMINSYN, alongside the launch of a long-term strategic partnership. The two sides will join forces to drive biotech innovation and sustainable development across the beauty industry.
This investment is led by Shanghai Meifang Investment Co., Ltd., an investment platform under L’Oréal China, with full backing from BOLD (Business Opportunities for L’Oréal Development), L’Oréal’s strategic innovation venture capital fund. Nice Group participated as a co-investor, with a combined investment of nearly RMB 100 million. Muyan Capital acted as the financial advisor for the transaction.
VEMINSYN’s selection by L’Oréal reflects its strong technological strengths and innovation potential. The company was a winner of the 2023 L’Oréal BIG BANG Beauty Technology Co-creation Program. Having stood out from more than 2,500 applicants and passed multiple rounds of review, it became one of only two Chinese startups in that year’s program to receive investment from L’Oréal – a clear demonstration of its excellence in biotechnology.
Under the cooperation agreement, the two parties will deepen their collaboration across three core areas:
Jointly develop innovative bioactive ingredients, combining VEMINSYN’s AI target screening and plant callus technologies with L'Oréal’s profound expertise in skin, hair and scalp biology, to create breakthrough cosmetic raw materials.
Accelerate the large-scale production of core ingredients, streamlining the workflow from laboratory R&D to industrial manufacturing and improving production efficiency.
Develop cosmetic raw materials using low-carbon biomanufacturing technologies, closely aligning with L'Oréal's Green Science strategy and supporting the industry’s low-carbon and sustainable development.
This investment is not only an important step for L'Oréal in building its local innovation ecosystem in China, but also a concrete practice of its “In China, For Global” innovation strategy.Vincent Boinay, President of L'Oréal North Asia and CEO of L'Oréal China, noted that the Chinese market holds tremendous innovation potential, and the partnership with VEMINSYN will fully combine the strengths of both sides to deliver sustainable innovation at greater speed.
Zhao Yaran, Founder and CEO of VEMINSYN, stated that this collaboration will accelerate the implementation of the company's “systematic innovation” philosophy, drive the scaled application of bioactive materials from lab to market, and inject new momentum into the global beauty industry.
To date, VEMINSYN has secured 158 raw material filings with the National Medical Products Administration (NMPA) and serves over 100 clients including L'Oréal, Nice Group and Bloomage Biotech. This partnership will further strengthen its industry influence and capabilities in technology commercialization.
